Novo Nordisk Shares Fall After Ziltivekimab Misses Primary Goal in Phase 3 ZEUS Heart Trial
The facts
- Novo Nordisk announced on July 31, 2026 that ziltivekimab did not reduce major adverse cardiovascular events versus placebo in the Phase 3 ZEUS trial, with a hazard ratio of 0.99 (95% confidence interval 0.88 to 1.11).
- ZEUS was a double-blind, placebo-controlled trial enrolling more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation defined as hsCRP of at least 2 mg/L, testing once-monthly subcutaneous ziltivekimab 15 mg.
- The drug did engage its intended target, producing the expected reductions in free IL-6 and high-sensitivity C-reactive protein, but this did not translate into fewer cardiovascular deaths, non-fatal heart attacks or non-fatal strokes.
- Novo Nordisk's shares fell on the announcement, dropping roughly 7% to 10% on the Copenhagen listing and about 9% to 10% for the U.S.-listed shares in premarket and early trading.
- Novo Nordisk said the trial result does not change its adjusted operating profit outlook for 2026, but that it will lead to a non-cash impairment charge in the third quarter.
- Two additional late-stage ziltivekimab trials — HERMES in heart failure and ARTEMIS in people who have had an acute heart attack — will continue, with results expected in the first half of 2027.
- Analysts had expected ziltivekimab to become a multibillion-dollar product that would help diversify Novo Nordisk's portfolio beyond its obesity and diabetes franchise; TD Cowen called the outcome a surprise and a major setback, and JPMorgan's Richard Vosser said the failure costs the company a multibillion-euro asset.
- Chief scientific officer Martin Holst Lange said the result was disappointing and that ZEUS had been designed to test whether IL-6 inhibition would convert reductions in cardiovascular inflammation into fewer cardiovascular events; the company said it remains committed to cardiovascular disease.
- The outcome raises questions about the broader strategy of targeting inflammation to prevent cardiovascular complications, and full ZEUS results are to be presented at an upcoming scientific meeting.
Context
What is ziltivekimab and what was ZEUS testing?
Ziltivekimab is a monoclonal antibody given as a once-monthly injection that targets the IL-6 ligand, a protein involved in chronic inflammation and the liver's release of C-reactive protein Superhits 97.9 Terr…,Motley Fool. ZEUS was designed to test whether blocking the IL-6 pathway could turn reductions in cardiovascular inflammation into fewer major cardiovascular events — defined as cardiovascular death, non-fatal heart attack or non-fatal stroke — in patients with atherosclerotic cardiovascular disease, chronic kidney disease and elevated hsCRP wallstreet:online,Manila times,cnbctv18.com.
Why does this matter beyond Novo Nordisk?
Because ziltivekimab lowered inflammatory markers without reducing cardiovascular events, investors and analysts treated the result as a test of the wider hypothesis that reducing cardiovascular inflammation prevents heart attacks and strokes STAT,Healio. Shares of other companies developing anti-inflammatory cardiovascular drugs fell sharply the same day, including BioAge Labs, whose lead oral NLRP3 inhibitor is in a Phase 2 trial, and Monte Rosa Therapeutics, which works in adjacent inflammatory pathways Investing.com,Investing.com.
What happens to the ziltivekimab program now?
Novo Nordisk said it will continue the two other ongoing late-stage trials, HERMES in heart failure and ARTEMIS in patients following an acute heart attack, with data expected in the first half of 2027 Morningstar,wallstreet:online,Motley Fool. Reporting notes that some analysts are skeptical those trials can salvage the program after the ZEUS miss FierceBiotech - fre….
Were there safety concerns in the trial?
Novo Nordisk said overall rates of adverse events were similar between patients who received ziltivekimab and those who received placebo Morningstar,Yahoo! Finance. The company described the announcement as headline results, with full data to be presented at a scientific meeting Manila times,Healio.
Common ground, and where they split
- Common ground
- A drug that hit its biomarker targets exactly as designed still prevented no deaths, heart attacks or strokes — and both reads treat the honest disclosure of that null result as the valuable part.
- Where Left and Right split
- Hard outcome trials proving that lowered inflammation markers are not patient benefit, or a market and a company absorbing a failed bet in hours without hiding it.
How left and right read it
More than 6,300 people with atherosclerotic heart disease and chronic kidney disease sat through a placebo-controlled trial that produced a hazard ratio of 0.99. The drug lowered IL-6 and hsCRP exactly as designed, and none of it prevented a single extra death, heart attack or stroke. That is the point of hard outcome trials. Biomarkers are not benefit, and patients — not the multibillion-euro asset analysts priced in — are what the evidence has to answer to.
Novo Nordisk announced on July 31, 2026 that ziltivekimab missed on major cardiovascular events, and shares repriced 7% to 10% in Copenhagen and roughly 9% to 10% in the U.S. within hours. That is a price signal doing its job. The company disclosed the miss, booked the non-cash impairment, held its 2026 profit outlook and kept HERMES and ARTEMIS running — honest accounting of a failed bet, which is precisely what should keep private risk capital funding the next one.
The receipts — 44 sources
Wire services (1)
Other coverage (43)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.